Tristan Imbert Appointed as Independent Director at EUROAPI

EUROAPI has announced the co-option of Tristan Imbert as an Independent Director, following the resignation of Rodolfo Savitzky. This decision, recommended by the Nominations and Compensation Committee, awaits approval at EUROAPI’s Shareholders’ meeting on May 27, 2026. Imbert will also become Chair of the Audit Committee on January 1, 2026, succeeding Savitzky.

With an extensive background in the pharmaceutical industry, Tristan Imbert's career began in R&D at Sanofi Aventis. He later joined Boston Consulting Group, advising on pharmaceutical projects, and subsequently held finance roles at Novartis and Cimeio Therapeutics. Imbert holds degrees in applied mathematics and an MBA.

Emmanuel Blin, EUROAPI’s Chairman, has expressed enthusiasm for Imbert's expertise in Finance, R&D, and Strategy, which is expected to benefit the board significantly.